665 research outputs found
Advances in platelet function testing—light transmission aggregometry and beyond
Platelet function testing is essential for the diagnosis of hemostasis disorders. While there
are many methods used to test platelet function for research purposes, standardization is often
lacking, limiting their use in clinical practice. Light transmission aggregometry has been the gold
standard for over 60 years, with inherent challenges of working with live dynamic cells in specialized
laboratories with independent protocols. In recent years, standardization efforts have brought
forward fully automated systems that could lead to more widespread use. Additionally, new technical
approaches appear promising for the future of specialized hematology laboratories. This review
presents developments in platelet function testing for clinical applications
Heparin Calibrated Anti-Xa Assays for the Measurement of Low Levels of Direct Factor Xa Inhibitors
Long-Term Survival, Vascular Occlusive Events and Efficacy Biomarkers of First-Line Treatment of CML:A Meta-Analysis
Large randomized clinical trials and prior meta-analyses indicate that second-generation BCR-ABL tyrosine kinase inhibitors (TKIs) improve surrogate biomarkers in patients with chronic myeloid leukemia (CML) without providing survival benefits. The objective is to evaluate the long-term efficacy and the occurrence of vascular occlusion with second-generation BCR-ABL TKIs compared with imatinib in patients with CML. Three scientific databases, a clinical registry and abstracts from congress were searched to identify all randomized controlled trials that compared a second-generation BCR-ABL TKI to imatinib in patients with CML. Outcomes extracted were overall survival, major molecular response and complete cytogenetic response, arterial occlusive events and venous thromboembolism. These data were synthesized by odds ratios using a fixed-effect model. This meta-analysis included 4659 participants from 14 trials. Second-generation BCR-ABL TKIs did not improve overall survival compared with imatinib, even at longer follow-up (OR, 1.17 (95% CI, 0.91-1.52)). They improved surrogate biomarkers at 12 and 24 months but increased the risk of arterial occlusion (OR, 2.81 (95% CI, 2.11-3.73)). The long-term benefits of second-generation TKIs are restricted to surrogate outcomes and do not translate into prolonged survival compared to imatinib. Given the long-term use, frontline therapy should be chosen carefully, with special attention to the patients' quality of life and cardiovascular risks
Influence of C-reactive protein on thrombin generation assay
To the editors, A close association between inflammatory state,C-reactive protein (CRP) and thromboembolic eventshas been described at least a decade ago [1] but hasresurfaced recently with the outbreak of the severe acuterespiratory syndrome coronavirus 2 (SARS-CoV-2) [...
Removal of DOACs from plasma:performance comparison and pre-analytical considerations of three different devices
Removal of DOACs from plasma:performance comparison and pre-analytical considerations of three different devices
Meta-analysis of the risks of arterial and venous occlusive events with new generation BCR-ABL TKIs in patients with chronic myeloid leukaemia
Meta-analysis of the risks of arterial and venous occlusive events with new generation BCR-ABL TKIs in patients with chronic myeloid leukaemia
Cardiovascular effect of BCR-ABL TKIs: a meta-analysis and systematic review of arterial and venous occlusive events
- …